Orlando Antelope

Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants

Christopher A. Eide, Matthew S. Zabriskie, Samantha L. Savage et al. · Cancer Cell · 2019 · 239 citations · Full text

Allosteric Inhibitor Asciminib, Medicine, Immunology +8

Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib

Wenan Qiang, Orlando Antelope, Matthew S. Zabriskie et al. · Leukemia · 2017 · 73 citations · Full text

Molecular Pharmacology, Medicine, Mechanism Of Action +4

SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia

Dongqing Yan, Anca Franzini, Anthony D. Pomicter et al. · Blood Cancer Discovery · 2021 · 57 citations · Full text

BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia

Orlando Antelope, Nadeem A. Vellore, Anthony D. Pomicter et al. · Experimental Hematology · 2019 · 27 citations · Full text

Hematological Malignancy, Engineering, Preclinical Activity +9

Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms

Ami B. Patel, Anthony D. Pomicter, Dongqing Yan et al. · Leukemia · 2020 · 15 citations · Full text

Tumor Biology, Novel Therapy, Multiple Mechanisms +9